ClinicalTrials.gov
ClinicalTrials.gov Menu

LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00567619
Recruitment Status : Completed
First Posted : December 5, 2007
Last Update Posted : February 18, 2008
Sponsor:
Information provided by:
AstraZeneca

September 20, 2007
December 5, 2007
February 18, 2008
July 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00567619 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency & severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists

- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
GERD
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
900
Same as current
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with newly occured upper GI symptoms related to GERD
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT00567619
NIS-GAT-NEX-2007/1
Not Provided
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Chair: Not required for Study Not required for this study
AstraZeneca
February 2008